Delek Group’s NovoCure NVCR Stock Holding History

Delek Group’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$2.21M	Buy	35,856 +2,188	+6%	+$111K	0.09%	145
2019 Q1	$1.61M	Buy	+33,668	New	+$1.62M	0.07%	149

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCP

Darsana Capital Partners New York $22.3B AUM 42.01% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Delek Group's NVCR Position: Q2 2019 in Review

Delek Group increased its NovoCure (NVCR) stake by 6.5% in Q2 2019, buying an estimated $111K and bringing the position to 35,856 shares worth $2.21M. The position accounts for 0.09% of the portfolio, ranked #145.

Delek Group first reported a position in NVCR in Q1 2019 and has held it in 2 quarters since. 197 funds tracked by Wall St. Rank hold NVCR as of Q2 2019.

Delek Group held 35,856 shares of NovoCure worth $2.21M as of Q2 2019.
Delek Group bought 2,188 NovoCure shares in Q2 2019, an estimated $111K.
NovoCure made up 0.09% of Delek Group's portfolio in Q2 2019, its #145 holding.
Delek Group first reported a position in NovoCure in Q1 2019 and has held it in 2 quarters since.
197 funds tracked by Wall St. Rank held NovoCure as of Q2 2019.

Based on Delek Group's 13F filing for Q2 2019, filed 8 Aug 2019.